IL139828A0 - COMPOUNDS HAVING IgE AFFECTING PROPERTIES - Google Patents

COMPOUNDS HAVING IgE AFFECTING PROPERTIES

Info

Publication number
IL139828A0
IL139828A0 IL13982899A IL13982899A IL139828A0 IL 139828 A0 IL139828 A0 IL 139828A0 IL 13982899 A IL13982899 A IL 13982899A IL 13982899 A IL13982899 A IL 13982899A IL 139828 A0 IL139828 A0 IL 139828A0
Authority
IL
Israel
Prior art keywords
ige
compounds
affecting properties
affecting
properties
Prior art date
Application number
IL13982899A
Other languages
English (en)
Original Assignee
Avanir Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22198947&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL139828(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Avanir Pharmaceuticals filed Critical Avanir Pharmaceuticals
Publication of IL139828A0 publication Critical patent/IL139828A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL13982899A 1998-05-22 1999-05-21 COMPOUNDS HAVING IgE AFFECTING PROPERTIES IL139828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8649498P 1998-05-22 1998-05-22
PCT/US1999/011363 WO1999061013A2 (en) 1998-05-22 1999-05-21 COMPOUNDS HAVING IgE AFFECTING PROPERTIES

Publications (1)

Publication Number Publication Date
IL139828A0 true IL139828A0 (en) 2002-02-10

Family

ID=22198947

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13982699A IL139826A0 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE
IL13982899A IL139828A0 (en) 1998-05-22 1999-05-21 COMPOUNDS HAVING IgE AFFECTING PROPERTIES
IL13982799A IL139827A0 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL13982699A IL139826A0 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13982799A IL139827A0 (en) 1998-05-22 1999-05-21 BENZIMIDAZOLE ANALOGS AS DOWN-REGULATORS OF IgE

Country Status (22)

Country Link
US (2) US6271390B1 (ko)
EP (3) EP1077695A2 (ko)
JP (3) JP2002516276A (ko)
KR (1) KR100591652B1 (ko)
CN (4) CN1311675A (ko)
AT (1) ATE292465T1 (ko)
AU (3) AU754943B2 (ko)
BR (3) BR9910642A (ko)
CA (3) CA2332985A1 (ko)
CZ (2) CZ20004350A3 (ko)
DE (1) DE69924607T2 (ko)
ES (1) ES2241285T3 (ko)
HU (3) HUP0101894A3 (ko)
IL (3) IL139826A0 (ko)
MX (3) MXPA00011467A (ko)
NO (3) NO20005887L (ko)
NZ (2) NZ508413A (ko)
PL (3) PL345952A1 (ko)
RU (2) RU2236221C2 (ko)
UA (2) UA67775C2 (ko)
WO (3) WO1999061013A2 (ko)
ZA (3) ZA200007754B (ko)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077695A2 (en) * 1998-05-22 2001-02-28 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
EP1113000A4 (en) * 1998-09-11 2004-12-15 Ajinomoto Kk BENZENE DERIVATIVES AND THEIR MEDICAL APPLICATION
US6270746B1 (en) * 1999-02-17 2001-08-07 David H. Katz Assay for the identification of IgE antibody suppressors
TR200102790T2 (tr) * 1999-03-26 2002-06-21 Euro-Celtique S.A. Aril İkameli Pirazoller, İmidazoller, Oksazoller, Tiazoller ve Piroller Ve Bunların Kullanımı.
CN1372548A (zh) * 1999-07-01 2002-10-02 味之素株式会社 杂环化合物及其医药用途
AU6866700A (en) 1999-09-01 2001-03-26 Ajinomoto Co., Inc. Biscyclopropanecarboxylic acid amide compounds and medicinal use thereof
US6759425B2 (en) 1999-10-21 2004-07-06 Avanir Pharmaceuticals Benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
WO2002072090A1 (en) * 2001-03-12 2002-09-19 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
NZ530580A (en) 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2464000C (en) 2001-10-19 2011-04-19 Ortho-Mcneil Pharmaceutical, Inc. 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer
US20080081788A1 (en) * 2002-01-14 2008-04-03 Lipps Binie V Diagnosis and treatment for immunoglobulin E (IgE) implicated disorders
US20030157555A1 (en) * 2002-01-14 2003-08-21 Lipps Binie V. Diagnosis and treatment for immunoglobulin E ( IgE) implicated disorders
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
EP1388535A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylated arylcycloalkylamines and their use as pharmaceuticals
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
TWI276631B (en) 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2004041280A1 (en) * 2002-11-02 2004-05-21 Kyung-Lim Lee Composition for preventing secretion of immunoglobulin e-dependent histamine releasing factor
GB2397301A (en) * 2003-01-14 2004-07-21 Novo Pharmaceuticals Ltd De Substituted 1,3,5-triazine derivatives
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
WO2005013950A2 (en) * 2003-08-08 2005-02-17 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
DK1718608T3 (da) 2004-02-20 2013-10-14 Boehringer Ingelheim Int Virale polymeraseinhibitorer
RU2381213C2 (ru) * 2004-05-12 2010-02-10 Протеотек, Инк. Замещенные n-арилбензамиды и родственные соединения для лечения амилоидных заболеваний и синуклеинопатии
DE602005027739D1 (de) 2004-06-30 2011-06-09 Janssen Pharmaceutica Nv Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
WO2006040645A1 (en) * 2004-10-11 2006-04-20 Ranbaxy Laboratories Limited N-(3,5-dichloropyridin-4-yl)-2,4,5-alkoxy and 2,3,4-alkoxy benzamide derivatives as pde-iv (phophodiesterase type-iv) inhibitors for the treatment of inflammatory diseases such as asthma
CA2627722A1 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
EP1790345A1 (en) * 2005-11-02 2007-05-30 Esbatech AG Triazin beta-secretase inhibitors
EP2016065B1 (en) * 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
ES2599319T3 (es) 2006-06-26 2017-02-01 Macrogenics, Inc. Anticuerpos específicos de Fc RIIB y métodos de uso de éstos
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
CN102245604A (zh) 2008-12-23 2011-11-16 雅培制药有限公司 抗病毒化合物
JP2012513409A (ja) 2008-12-23 2012-06-14 アボット・ラボラトリーズ 抗ウイルス化合物
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
TWI469780B (zh) 2009-06-11 2015-01-21 Abbvie Bahamas Ltd 抗病毒化合物
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
JP5690839B2 (ja) * 2009-12-04 2015-03-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン産生のベンゾイミダゾール阻害薬
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
DK2595965T3 (en) 2010-07-20 2016-08-22 Vestaron Corp Insecticidal triazines and pyrimidines
JP5928958B2 (ja) 2010-10-29 2016-06-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
US8772304B2 (en) 2010-11-01 2014-07-08 Boehringer Ingelheim International Gmbh Benzimidazole inhibitors of leukotriene production
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
WO2019018562A1 (en) 2017-07-19 2019-01-24 Ideaya Biosciences, Inc. AMIDO COMPOUND AS MODULATORS OF AHR
WO2020061086A2 (en) * 2018-09-18 2020-03-26 Terns, Inc. Compounds for treating certain leukemias
CN110054558B (zh) * 2019-05-16 2022-03-25 海门瑞一医药科技有限公司 一种1-三氟甲基环丙烷-1-甲酸的制备方法
CN112441983B (zh) * 2019-08-29 2023-09-15 山东福长药业有限公司 一种基于苯并咪唑取代的硝基苯的化合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3017610A (en) * 1957-03-15 1962-01-16 Curtiss Wright Corp Electronic data file processor
US4939133A (en) 1985-10-01 1990-07-03 Warner-Lambert Company N-substituted-2-hydroxy-α-oxo-benzeneacetamides and pharmaceutical compositions having activity as modulators of the arachidonic acid cascade
LU86258A1 (fr) * 1986-01-21 1987-09-03 Rech Dermatologiques C I R D S Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
US4744026A (en) * 1986-04-11 1988-05-10 American Telephone And Telegraph Company, At&T Bell Laboratories Methods and apparatus for efficient resource allocation
IT1232252B (it) * 1989-02-22 1992-01-28 Rotta Research Lab Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione
DE59010069D1 (de) * 1989-11-21 1996-02-29 Bayer Ag Cumarinderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und Thiazolyl-essigsäurederivate als Zwischenprodukte
DE69113162T2 (de) 1990-08-02 1996-03-14 Hoffmann La Roche Antiallergische Mischung.
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
CA2114114C (en) 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
US5521813A (en) * 1993-01-15 1996-05-28 Strategic Weather Services System and method for the advanced prediction of weather impact on managerial planning applications
US5496826A (en) * 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPOSITIONS AND METHODS FOR TREATING CONDITIONS ASSOCIATED WITH BONE DEFICIT
US6988076B2 (en) * 1997-05-21 2006-01-17 Khimetrics, Inc. Strategic planning and optimization system
EP1077695A2 (en) * 1998-05-22 2001-02-28 Avanir Pharmaceuticals COMPOUNDS HAVING IgE AFFECTING PROPERTIES
US6910017B1 (en) * 1999-03-05 2005-06-21 Profitlogic, Inc. Inventory and price decision support
US6405175B1 (en) * 1999-07-27 2002-06-11 David Way Ng Shopping scouts web site for rewarding customer referrals on product and price information with rewards scaled by the number of shoppers using the information
US6546387B1 (en) * 1999-11-15 2003-04-08 Transcom Software Inc. Computer network information management system and method using intelligent software agents
US20020042739A1 (en) * 2000-03-13 2002-04-11 Kannan Srinivasan Method and system for creating and administering internet marketing promotions
US20020023001A1 (en) * 2000-07-11 2002-02-21 Mcfarlin James A. Method and apparatus for online creation and sale of custom local store marketing materials
AU2002219791A1 (en) * 2000-11-15 2002-05-27 Manugistics Atlanta, Inc. Promotion pricing system and method
US20020198794A1 (en) * 2001-06-21 2002-12-26 Williams Edward P. Inventory management system for determining suggested part stocking levels for a vehicle dealer

Also Published As

Publication number Publication date
PL345219A1 (en) 2001-12-03
CA2332989A1 (en) 1999-12-02
CZ20004350A3 (cs) 2002-02-13
IL139827A0 (en) 2002-02-10
CA2332985A1 (en) 1999-12-02
UA67775C2 (uk) 2004-07-15
IL139826A0 (en) 2002-02-10
NO20005888L (no) 2001-01-22
RU2236221C2 (ru) 2004-09-20
DE69924607T2 (de) 2006-02-02
HUP0102128A3 (en) 2002-05-28
US6271390B1 (en) 2001-08-07
KR20010030179A (ko) 2001-04-16
HUP0102550A2 (hu) 2001-10-28
EP1079830A1 (en) 2001-03-07
AU4197899A (en) 1999-12-13
CN1317965A (zh) 2001-10-17
CN1311679A (zh) 2001-09-05
AU754562B2 (en) 2002-11-21
AU4312099A (en) 1999-12-13
ZA200007753B (en) 2001-07-18
JP2002516274A (ja) 2002-06-04
WO1999061019A1 (en) 1999-12-02
EP1077695A2 (en) 2001-02-28
ATE292465T1 (de) 2005-04-15
AU4094299A (en) 1999-12-13
CA2332999A1 (en) 1999-12-02
CN1311675A (zh) 2001-09-05
KR100591652B1 (ko) 2006-06-26
NZ508416A (en) 2004-01-30
HUP0102550A3 (en) 2002-11-28
NO20005889D0 (no) 2000-11-21
NZ508413A (en) 2003-08-29
BR9910640A (pt) 2001-10-30
ZA200007752B (en) 2001-12-05
NO20005887L (no) 2001-01-19
CZ20004351A3 (cs) 2001-10-17
BR9910642A (pt) 2001-10-09
PL345952A1 (en) 2002-01-14
MXPA00011422A (es) 2002-12-13
MXPA00011470A (es) 2002-10-17
EP1077700A1 (en) 2001-02-28
US6451829B2 (en) 2002-09-17
WO1999061013A2 (en) 1999-12-02
CN1721411A (zh) 2006-01-18
HUP0102128A2 (hu) 2002-03-28
UA67774C2 (uk) 2004-07-15
NO20005888D0 (no) 2000-11-21
RU2236220C2 (ru) 2004-09-20
PL345560A1 (en) 2001-12-17
AU754943B2 (en) 2002-11-28
US20020010343A1 (en) 2002-01-24
MXPA00011467A (es) 2002-10-17
WO1999061020A1 (en) 1999-12-02
NO20005889L (no) 2001-01-22
JP2002516276A (ja) 2002-06-04
HUP0101894A3 (en) 2002-07-29
WO1999061013A3 (en) 2000-04-06
CN1219510C (zh) 2005-09-21
JP2002516277A (ja) 2002-06-04
NO20005887D0 (no) 2000-11-21
DE69924607D1 (de) 2005-05-12
HUP0101894A2 (hu) 2002-02-28
EP1077700B1 (en) 2005-04-06
ES2241285T3 (es) 2005-10-16
ZA200007754B (en) 2001-08-16
BR9910641A (pt) 2001-10-02

Similar Documents

Publication Publication Date Title
PL345219A1 (en) Compounds having ige affecting properties
MXJL03000027A (es) Compuestos de benzimidazol para modular la ige e inhibir la proliferacion celular.
WO2004024897A3 (en) PHENYL-AZA-BENZIMIDAZOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2002002505A8 (en) Compounds to treat alzheimer's disease
WO2002002512A3 (en) Compounds to treat alzheimer's disease
WO2002002520A3 (en) Compounds to treat alzheimer's disease
ATE326239T1 (de) Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
MXJL05000009A (es) Compuestos de fenilindon para modular la ige e inhibir la proliferacion celular.
HK1097841A1 (en) Multicyclic compounds and their use as inhibitors of parp, vegfr2 and mlk3 enzymes
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
TW200503695A (en) Imidazole derivatives for treatment of allergic and hyperproliferative disorders
SE0302304D0 (sv) Novel compounds
ATE295724T1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
SE9901273D0 (sv) Novel compounds
PT1032415E (pt) Prevencao e/ou tratamento de condicoes alergicas
PT828483E (pt) Utilizacao de derivados de tropolona como inibidores da enzima inositol monofosfatase
TJ387B (en) The present invention relates to medicine and can be used for treatment of inflammatory process of aleather.
YU80003A (sh) Upotreba proteina uk114 ili njegovih fragmenata za tretman i prevenciju endotoksičnog šoka